Phase 3 Hypertension Trial, Recruiting (NCT06111079)

Phase 3 Hypertension Trial, Recruiting NCT06111079 Sponsor: FANG HE Condition: Hypertension

Printed from Voxsanity (voxsanity.com.au) — NCT06111079 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hypertension

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are less than 16 weeks pregnant and have had a normal nuchal translucency (NT) scan, which is a routine early pregnancy ultrasound
People who have at least one high-risk factor, or at least two moderate-risk factors, for pregnancy complications (confirm with trial site for which factors qualify)
People who plan to have their prenatal check-ups and give birth at the hospital running this trial
People who have read and signed a consent form agreeing to take part in the study

Who may not be able to join:

People who started taking aspirin after 16 weeks of pregnancy
People who cannot tolerate aspirin or have an allergy to it
People whose aspirin use during the study was less than 80% of the required doses
People who experienced a miscarriage or ended their pregnancy before being assigned to a study group
People who did not return to the hospital for their delivery
People who were lost to follow-up, meaning the study team was unable to continue tracking their progress

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 9 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Fang He, M.D, The Third Affiliated Hospital of Guangzhou Medical University

Phone: +86 13724831279

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06111079

Sponsor: FANG HE

Phase: Phase 3

Status: Recruiting

Condition: Hypertension

Trial contact: +86 13724831279

More information: https://clinicaltrials.gov/study/NCT06111079

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are less than 16 weeks pregnant and have had a normal nuchal translucency (NT) scan, which is a routine early pregnancy ultrasound
People who have at least one high-risk factor, or at least two moderate-risk factors, for pregnancy complications (confirm with trial site for which factors qualify)
People who plan to have their prenatal check-ups and give birth at the hospital running this trial
People who have read and signed a consent form agreeing to take part in the study

Who may not be able to join:

People who started taking aspirin after 16 weeks of pregnancy
People who cannot tolerate aspirin or have an allergy to it
People whose aspirin use during the study was less than 80% of the required doses
People who experienced a miscarriage or ended their pregnancy before being assigned to a study group
People who did not return to the hospital for their delivery
People who were lost to follow-up, meaning the study team was unable to continue tracking their progress

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 9 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

FANG HE

Registry

ClinicalTrials.gov

Start date

1 November 2023

Est. completion

30 December 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of preterm preeclampsia

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov